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Abstract.  
Nontuberculous mycobacteria are ubiquitous environmental organisms that have been 
recognised as a cause of pulmonary infection for over 50 years. Traditionally patients 
have had underlying risk factors for development of disease; however the proportion of 
apparently immunocompetent patients involved appears to be rising. Not all patients 
culture-positive for mycobacteria will have progressive disease, making the diagnosis 
difficult, though criteria to aid in this process are available. The two main forms of 
disease are cavitary disease (usually involving the upper lobes) and fibronodular 
bronchiectasis (predominantly middle and lingular lobes). For patients with disease, 
combination antibiotic therapy for 12-24 months is generally required for successful 
treatment, and this may be accompanied by drug intolerances and side effects. Published 
success rates range from 30-82%. As the progression of disease is variable, for some 
patients, attention to pulmonary hygiene and underlying diseases without immediate 
antimycobacterial therapy may be more appropriate.  Surgery can be a useful adjunct, 
though is associated with risks. Randomised controlled trials in well described patients 
would provide stronger evidence-based data to guide therapy of NTM lung diseases, and 
thus are much needed.  
 
Key words: mycobacteria, nontuberculous; anti-mycobacterial therapeutics; lung 
diseases; bronchiectasis; 
Short title: Treatment of pulmonary NTM disease.  
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INTRODUCTION 
Nontuberculous mycobacteria (NTM) generally refer to mycobacteria other than 
Mycobacterium tuberculosis complex and Mycobacterium leprae.  They are commonly 
occurring microbes that have differing geographic distributions worldwide in 
environmental reservoirs, particularly the soil and various water sources.1 The mode of 
transmission of NTM to humans has not been fully delineated, although person-to-person 
transmission is thought not to occur, at least in immunocompetent hosts. 
EPIDEMIOLOGY OF PULMONARY NTM INFECTIONS 
An increase in the prevalence of NTM infection/disease worldwide has been 
noted in the past 1 – 2 decades.2-4 Postulated reasons include (1) a rise in prevalence of 
HIV infection and other acquired immunocompromised states, (2) an increased 
understanding of the clinico-pathological relationship between host and pathogen5 and 
awareness of these organisms as potential pathogens, (3) advances in methods of 
detection and recovery of the organisms, (4) an aging population (as this is often a 
disease of the elderly), (5) increased survival of patients with conditions that increase 
susceptibility – such as cystic fibrosis and COPD and (6) increased environmental 
exposure. Factors driving this increase in exposure include (i) disinfection of drinking 
water with chlorine, selecting mycobacteria by reducing competition; and (ii) disinfection 
attempts in medical and industrial settings
In 1999 – 2000, an estimated 1 in 6 persons in the United States of America (U.S.A.) 
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demonstrated Mycobacterium intracellulare sensitization, up from 1 in 9 persons in 
1971 – 1972.  This observed rising prevalence of sensitization (as a measure of increased 
exposure) has paralleled the increase in rate of pulmonary NTM infections.6 A similar 
increase in NTM infections has also occurred in the Asia-Pacific region.2,7 In Queensland, 
Australia, where NTM disease is notifiable and a central laboratory performs all 
mycobacterial speciation, speciated pulmonary isolates from patients increased from 5.5 
to 10.2 per 100 000 population between 1999 and 2005. M. intracellulare accounted for 
most of this increase. Significant pulmonary disease rose from 2.2 to 3.2 per 100 000 
(unpublished data). Marras, et al reported a similar increase in Ontario, Canada between 
1997-2003.4
Mycobacterium avium complex (MAC), Mycobacterium kansasii, and rapidly growing 
mycobacteria (RGM) such as M. abscessus and M. fortuitum constitute the main species 
associated with human pulmonary disease.7-9 While the underlying reason has not been 
totally unravelled, the higher innate resistance of MAC to chlorine and ozone, in 
comparison to other NTM, might help to explain the phenomenon.  Other important 
NTM that can cause pulmonary infections / diseases are Mycobacterium xenopi,
Mycobacterium malmoense, and Mycobacterium szulgai.7-9 
DIAGNOSIS OF PULMONARY NTM DISEASES 
Clinical Features of NTM Lung Diseases 
Pulmonary diseases due to NTM generally belong to one of the following 4 
patterns.  (1) Fibrocavitary disease (Figure 1) classically involves the upper lobes of 
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middle-aged men with histories of smoking and alcoholism, and often with underlying 
lung diseases like COPD, previous tuberculosis, and silicosis. This form of disease is 
particularly associated with MAC, M. kansasii,10 M. xenopi,11 M. malmoense,12 and 
RGM.13 (2) Nodular bronchiectasis (Figure 2) generally involves elderly non-smoking 
females with no underlying lung disease, but who may have thoracic deformities like 
pectus excavatum, kyphosis and scoliosis.14  (3) Solitary pulmonary nodule15-19 presents 
very much like a tuberculoma, and has to be differentiated from a carcinoma.16 (4) 
Hypersensitivity pneumonitis occurs in previously healthy subjects with exposure to 
contaminated indoor hot tubs19 or contaminated metal working fluids.20, 21  
In the interpretation of the literature on NTM disease, it is important to appreciate the 
proportion of patients in each of the above groups. There is a feeling among clinicians 
that the cavitary form of disease is becoming less common, whilst the nodular 
bronchiectatic form is more prevalent. This has important implications for treatment trials 
and epidemiological studies.  
 
Chronic obstructive pulmonary disease,3 cystic fibrosis,22 gastroesophageal reflux disease 
and vomiting,23 and chest wall disorders,14 have all been associated with NTM lung 
diseases. One large, multicentre study reported that NTM were isolated from the 
respiratory secretions of 13% of patients with cystic fibrosis.22 Recently, NTM and 
bronchiectasis together have been found to be associated with a higher risk of Aspergillus 
lung disease.24 The association between NTM colonisation / infection and unselected 
cases of bronchiectasis still remains elusive, though it is likely that bronchiectasis acts as 
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a predisposing underlying lung disease. 
 
The signs and symptoms of NTM lung diseases are generally nonspecific.  Malaise and 
chronic cough (with and without sputum production) are very common.  Dyspnoea is 
more related to underlying lung disease (except with hypersensitivity pneumonitis). 
Occasional patients with the nodular bronchiectasis can have bronchiolitis and gas 
trapping associated with dyspnoea. Fatigue, weight loss, and sweats also occur 
particularly as disease progresses.  Haemoptysis occurs in more advanced lung disease, 
especially with cavitation and advanced bronchiectasis.  
Radiographic Assessment of NTM Lung Diseases 
 Cavitary NTM disease can be readily assessed by plain chest radiograph.  The 
cavities are said to have thinner walls, and are associated with less surrounding 
parenchymal lesions, but more pleural reactions than those of tuberculosis.  Other forms 
of NTM lung disease are better assessed by high resolution computed tomography 
(HRCT).  The prevalent HRCT findings are bilateral centrilobular nodules, and 
cylindrical bronchiectasis.25 These changes correlate with bronchiolar / peribronchiolar 
inflammation due to tissue invasion by NTM like MAC and M. abscessus.5 It has been 
suggested that about 30% of patients with changes of bilateral bronchiectasis and 
bronchiolitis on HRCT had NTM disease;26 extensive radiographic abnormalities, 
cavitation or consolidation, and female gender provided additional risks.  Classically, 
multifocal bronchiectasis and diffuse centrilobular nodules, especially involving the 
middle and lingular lobes found in elderly nonsmoking females has been referred to as 
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the Lady Windermere syndrome.27 Serial CT scanning in MAC lung disease has shown 
that bronchiectasis tends to be progressive, alongside spread of nodules.  Finally 
progression to consolidation can also occur.28,29 
In “hot tub” lung due to MAC-associated hypersensitivity pneumonitis, chest CT often 
demonstrates diffuse ground-glass infiltrates and centrilobular nodules.30  A similar 
clinical and radiological syndrome occurs after exposure to metalworking fluid 
contaminated with M. immunogenum, a RGM closely related to M. abscessus. 20,21 
Solitary pulmonary nodules or masses have been described in several NTM lung 
diseases,15,17 though apparently rare. 
 
Identification of NTM and Drug Susceptibility Testing 
 NTM can be divided into slowly growing mycobacteria and rapidly growing 
mycobacteria (Table 1). The former constitute members of the Runyon group I to group 
III, whereas the latter are equivalent to members of the Runyon group IV.31  Using 
modern microbiology laboratory methods, including liquid culture media, NTM growth 
can be detected by culture from patient specimens 1 – 3 weeks after incubation.32  Most 
rapid growing NTM will grow in 7 - 10 days. Slow growers can grow in 1-3 weeks, but 
may take much longer. Cultures are usually kept for 6-8 weeks before being regarded as 
negative. In patients with chronic bronchial sepsis, such as cystic fibrosis and 
bronchiectasis, where colonisation by Pseudomonas aeruginosa and other bacterial 
pathogens prevails, sputum specimens can be overgrown before NTM growth appears. 
Special decontamination methods are often necessary to reduce this overgrowth.  
Decontamination unfortunately reduces the yield of mycobacteria also, and persistence is 
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needed if there is a clinical suspicion of NTM disease in these patients.  
 
Although semiquantitative smear and culture results were used previously as NTM 
diagnostic criteria,33 the current use of liquid media has put less emphasis on such an 
approach.  With recovery of the organism by culture, DNA probes are commercially 
available to identify some of the NTM – MAC, M. kansasii and M. gordonae. Other 
organisms have traditionally been identified by a combination of biochemical testing and 
high-performance liquid chromatography.  DNA amplification with polymerase chain 
reactions (PCR) has emerged as a technique to aid the rapid identification of 
mycobacterial isolates.  One such approach utilises a multiplex PCR34 to identify multiple 
mycobacterial pathogens. Partial sequencing of a segment of 16S ribosomal RNA, 
sometimes complemented by sequencing of the 16S-23S internal transcribed spacer, has 
been used35,36 to identify those species not identified by other means.  
Clinically significant NTM isolates should be identified to the species level, except 
perhaps for M. avium and M. intracellulare.37 The American Thoracic Society / Infectious 
Diseases Society of America (ATS/IDSA) guidelines state that routine testing of MAC 
species for antimicrobial susceptibility (other than clarithromycin) is not generally 
recommended because of the paucity of evidence correlating in vitro results and in vivo 
(clinical) response.37 However it has been postulated that drug combinations can produce 
synergistic activity, in both in vitro and in vivo settings.38,39 Some authors have shown a 
relationship between clinical response to treatment and administration of drugs to which 
the strains had demonstrated susceptibility.40-43 Patients with nodular bronchiectasis may 
be infected with multiple strains and even species at different time points in their 
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disease;44 however the significance of this with respect to treatment and antibiotic 
susceptibility is uncertain. 
The ATS does recommend clarithromycin susceptibility testing for new, previously 
untreated MAC isolates37 as macrolide resistance has been associated with a poorer 
outcome. It should also be performed for MAC isolates from patients who have failed 
macrolide treatment, or who have relapsed from apparently successful treatment.  
Previously untreated M. kansasii strains should be tested in vitro to rifampicin only.37 M. 
kansasii isolates resistant to rifampicin should be tested against a panel of secondary 
agents, inclusive of rifabutin, ethambutol, isoniazid, clarithromycin, fluoroquinolones, 
amikacin and sulphonamides.  RGM should be tested against a panel of eight 
antimicrobials for susceptibility.37  This testing helps in identification of M. abscessus, M. 
chelonae and M. fortuitum, as well as, guidance of antimicrobial therapy.  The eight drugs 
are amikacin, cefoxitin, clarithromycin, ciprofloxacin, doxycycline, linezolid, 
sulphamethoxazole and tobramycin. 
 
Other Diagnostic Tests for NTM Lung Diseases 
 Skin test antigens specific for NTM species are no longer readily available for use.  
They do  exhibit cross-reaction with tuberculin and recent sequencing of the genome of 
M. avium has demonstrated that the strain of M. avium used in the avian skin test is not 
associated with human disease.45 The sensitivity, specificity and positive predictive value 
of PPD-B (M. intracellulare) and NTM disease were 70, 61 and 64% respectively in one 
study and the authors concluded it was no more useful in distinguishing pulmonary 
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disease due to NTM than PPD-T alone.46 Thus, skin testing using these antigens has little 
role in the diagnosis of NTM lung disease.   
New interferon-gamma release assays utilizing antigens largely specific for M. 
tuberculosis may help to differentiate active pulmonary tuberculosis from NTM lung 
disease,47,48 but these data are preliminary at present.  It is useful to note that the M. 
tuberculosis specific antigen, ESAT-6 is also present in M. kansasii, M. marinum and M. 
szulgai, and thus exposure to these NTM could result in false-positive test results.   
 
Diagnostic Criteria for NTM Lung Diseases 
 Not all patients who have mycobacteria cultured from sputum or bronchial 
specimens are considered to have disease. It has been postulated that they are transiently 
contaminated or colonized by these organisms and that ingested water or inhaled aerosols 
are the source of the organisms.49,50 Wolinsky51 described 3 stages of interaction between 
the organism and host – colonisation, infection and disease. The progression through 
these stages is dependent on the quantity of growth, repetitive isolation, the site of 
isolation, the species of organism and underlying host condition. Colonisation can be 
defined as repeated isolation of an organism without evidence of a host response. The 
concept of colonisation with nontuberculous mycobacteria in the lung without infection 
or invasion is debated.52 The ATS guidelines on the management of nontuberculous 
mycobacterial disease,33 state that “colonisation in the true sense (i.e. no tissue invasion) 
is probably quite rare”. 
The ATS have proposed criteria to differentiate between colonisation/contamination and 
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disease, and encompass bacteriological, radiological and clinical criteria (Table 2).37 The 
criteria of 2007 have relaxed the microbiologic criteria, as it is recognised that patients 
with nodular bronchiectasis have paucibacillary disease and shed organisms intermittently, 
and therefore it can be difficult to document positive specimens repeatedly. The 
bacteriologic criteria of 1997,33 may have led to an under-diagnosis of disease, yet the 
criteria from 2007 may allow over-diagnosis. Hence positive cultures need to be 
interpreted in light of the findings on CXR/HRCT (as a means of assessing tissue 
invasion/host response), and the symptoms, as well as underlying diseases of the patient.   
The significance of an isolate also varies with the species of mycobacteria. Isolation 
of mycobacteria like M. gordonae, M. mucogenicum, M. haemophilum, M. flavescens, M. 
gastri, M. terrae complex or M. triviale usually indicates transient colonisation or 
contamination though disease has been reported.  Because M. szulgai is rarely isolated 
from the environment, a single positive culture is usually pathologically significant.37 
Similarly, many would like to relax the bacteriological criteria for diagnosing M. kansaii 
lung disease, by allowing diagnosis of disease with a single positive culture result, 
provided the clinical and radiographic grounds are strong.53  
 In general, expert consultation should be obtained when NTM are recovered that are 
either infrequently encountered, or that usually represent environmental contaminants.  
Treatment recommendations for these NTM are usually made on the basis of only a few 
reported cases.  On the other hand, treatment recommendations for species like MAC and 
M. kansasii are generally more evidence based.  Empiric therapy for suspected NTM lung 
disease is not recommended. Such cases should be followed up closely, until diagnosis is 
firmly established or excluded.37 
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WHEN TO TREAT PULMONARY NTM DISEASES 
 Diagnosing pulmonary NTM infection/disease does not equate to the need for 
immediate treatment. Treatment constitutes an important undertaking for the physician 
and patient as it usually involves combination antibiotic therapy for 12- 24 months. In 
some cases disease remits spontaneously. Indeed, lung involvement may range in severity 
from subclinical / mild clinical (indolent) infection to disease associated with extensive 
invasion / destruction of the lungs.  Early studies of MAC disease demonstrated a 
variable progression of infection, but the majority of symptomatic (and some supposedly 
asymptomatic) patients had progressive disease, and often died as a result.54,55 However 
most of these early studies consisted of patients with cavitary disease, often associated 
with heavy smoking, COPD or other underlying lung disease, and alcohol excess – 
factors likely to affect mortality and response to treatment. There are few studies 
documenting the natural history of nodular bronchiectasis, which often occurs in the 
absence of significant co-morbidity; however it seems to be quite variable. Whilst the 
progression of disease is generally slower than in cavitary disease, it can lead to 
respiratory failure and death.56 There are also differences in the natural history of 
infection with different species and probably also between different strains within 
species.57 M.kansasii tends to be more associated with a tuberculosis-like illness, and is 
generally easier to treat – therefore the threshold for treatment with antimicrobials is 
somewhat lower, than for example, with M. abscessus. This latter pathogen is notoriously 
difficult to eradicate and requires a combination of injectable antibiotics. This prospect 
often raises the threshold for the institution of therapy. 
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Therefore the decision to treat, should involve a period of observation – usually for 
between 3 and 12 months- both for radiological and symptomatic progression. Apart from 
the usual symptoms of cough ± sputum production, weight loss, fevers and sweats, the 
occurrence of frequent intercurrent infections due to other bacteria may be a suggestion 
of underlying inflammation caused by the presence of mycobacterial infection.  
 
Factors to consider in the decision to treat also include the patient’s age and potential for 
progressive parenchymal damage due to NTM, leading to colonisation and infection with 
other pathogens (such as other species of mycobacteria, Pseudomonas aeruginosa,
Sternotrophomonas and Aspergillus). A younger patient (<75 yrs) without major 
comorbidity has more to lose in terms of quality of life if disease is left untreated than a 
patient in his / her 80’s with multiple comorbidities. It has been suggested that patients 
with more advanced radiological changes are less likely to respond to therapy58,59 – 
which would favour early treatment, particularly in the younger patient.  
 
Similarly – the presence of predisposing conditions, may affect the rate of progression of 
disease. Patients on immunosuppressive medication, or with hereditary disorders of 
immune function, may have more rapidly progressive disease and warrant earlier and 
more aggressive treatment. Patients with very little pulmonary reserve due to other 
disease (such as severe COPD, advanced bronchiectasis) may also warrant a more 
aggressive approach, as a delay in treatment whilst waiting for evidence of progressive 
NTM disease may contribute to significant morbidity.  
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In instituting therapy, there is a need to establish realistic expectations regarding 
outcomes.  In many patients the aim should be cure, and an aggressive approach 
warranted. In others it may simply be suppression in order to achieve symptom control. 
The cost, drug-drug interactions, side effects, and unclear impact of treatment on the 
quality and quantity of life should be considered.  For some patients close observation 
and use of adjunctive therapies, such as airway clearance techniques, attention to 
underlying lung disease, gastro-oesophageal reflux disease, swallowing disorders and 
nutrition, may be a reasonable option. The risks (including potential adverse reactions) 
and benefits (such as improvement in symptoms, preservation of lung function, reduced 
risk of added infections) of antimicrobial therapy should be extensively discussed with 
the patient prior to deciding whether to institute such therapy.   
 
HOW TO TREAT PULMONARY NTM DISEASES 
General Principles 
Patients respond best to NTM treatment the first time it is administered; therefore, 
it is very important that patients initially receive a recommended multidrug regimen.37,60 
During chemotherapy, long-term management consists of microbiological surveillance, 
management of drug toxicity, nutrition and comorbidities.   
Specific Antimicrobial Treatment Guidelines 
Only the pulmonary diseases due to the commonly encountered NTM organisms 
will be discussed below.  The British Thoracic Society (BTS),61 Japanese Society for 
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Tuberculosis (JST),62 and American Thoracic Society/Infectious Diseases Society of 
America (ATS/IDSA)37 have published guidelines for the management of disease due to 
nontuberculous mycobacteria. Whilst the British guidelines have not been updated since 
1999, a recent randomised controlled trial performed by the BTS,63 gives insight into 
their latest recommendations. The BTS guidelines are predominantly based on two large 
randomised controlled studies42,63 and historical studies performed in patients of the 
United Kingdom and Europe. The Japanese guidelines are very similar to those of the 
ATS/IDSA. The ATS/IDSA document is an extensive review of the available literature on 
NTM diseases combined with expert opinion, and the most recent version was published 
in 2007. The recommended treatment criteria are based on several smaller prospective 
non-randomised controlled studies (using historical controls), in U.S. patients. It is very 
difficult to compare the many different treatment studies done in pulmonary NTM 
disease. Geographic differences in patient populations, mix of disease type (i.e. nodular 
bronchiectasis vs cavitary disease), severity of disease, differing species of NTM, drugs 
used and dosages, and study design and analysis, are all factors contributing to the 
significant heterogeneity of findings and hence the recommendations made by the 
Societies.   
 
MAC lung disease
The treatment recommendations for MAC lung disease are summarised in Table 3.
The ATS/IDSA recommended initial regimen for patients with mild nodular-
bronchiectatic MAC lung disease is a three-times-weekly regimen including 
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clarithromycin  1,000 mg or azithromycin 500 mg, ethambutol 25 mg/kg, and rifampicin 
600 mg.37 Intermittent drug therapy is not recommended for patients with cavitary 
disease, patients who have been previously treated, or patients who have moderate to 
severe disease.37,64  
The ATS/IDSA recommended initial regimen for fibrocavitary or moderate to severe 
nodular-bronchiectatic MAC lung disease includes daily clarithromycin 500 – 1,000 
mg/day or azithromycin 250 mg/day, ethambutol (E) 15 mg/kg/day, and rifampicin (R) 10 
mg/kg/day (maximum 600 mg), assuming normal liver and renal status.  Lower doses of 
clarithromycin may be necessary in patients over 60 years of age who have low body 
weights.  Aminoglycosides should be considered in the initial phase and are 
recommended for patients with severe or previously treated disease.   
 
The ATS guided primary microbiological goal is 12 months of negative sputum cultures 
prior to stopping therapy,37 as counted from the first of at least three consecutive 
negative sputum cultures. Macrolides should not be used as monotherapy for MAC 
disease because of the risk for developing macrolide-resistant MAC isolates.65-67 
Macrolide-resistant MAC lung disease,67 is difficult to treat and often requires prolonged 
parenteral aminoglycoside therapy and surgery. Similar to the ATS/IDSA, the JTS 
recommends a combination of streptomycin, clarithromycin, E and R for all patients.  
 
In contrast, the BTS recommends two years of rifampicin (R) and ethambutol (E) ± 
isoniazid (H) for MAC disease.61 Its recent randomised controlled trial (RCT) compared 
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the addition of ciprofloxacin or clarithromycin to ER over 2 years.63 There was an 
additional option to compare M.vaccae immunotherapy in each arm. It is important to 
note that this study included 170 patients with MAC, 67% of whom had cavitary disease, 
and 54% had evidence of an underlying respiratory condition on CXR.  The authors 
concluded there was no additional benefit in adding either clarithromycin or 
ciprofloxacin to ER, as the number of patients alive and cured at 5 years were similar, 
both for each arm of the trial and the results of a previous trial comparing ER and ERH.  
ERH had the best success rate, but highest disease associated mortality. ERclarithromycin 
was associated with the highest all-cause mortality. Interestingly, the reported side effects 
leading to a change of treatment in the ERclarithromycin/ERciprofloxacin trial were 
twice that of the ER/ERH trial. As such, their suggested treatment regimen would be 24 
months ER with H or ciprofloxacin added at 12 months if patients were doing poorly. No 
analysis was performed according to radiological presentation as cavitary disease vs 
nodular bronchiectasis. Such data may be useful in assessing the relevance of the findings 
to these patient groups, as those with bronchiectasis may potentially benefit from both the 
anti-pseudomonal properties of ciprofloxacin, and the anti-inflammatory properties of 
clarithromycin. Similarly, the BTS makes no distinction in recommended therapy 
between the two radiological groups. 
 
There are still a number of controversies and unresolved questions in the management of 
MAC lung disease.  Firstly, there have been no head-to-head comparative trials between 
clarithromycin- and azithromycin-containing regimens for MAC lung disease.  Thus, 
there is no demonstrated superiority of one macrolide among the two agents regarding 
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efficacy or risk of resistance.  It is felt that macrolides have helped to improve treatment 
of MAC lung disease,59 though not all studies have supported this.63 It would appear that 
this assumption may be more valid for patients with nodular bronchiectasis, rather than 
cavitary disease with the results of clinical studies at variance.  If patients have not been 
pre-treated and are able to tolerate the medications for the required period of time, 
sputum conversion may be up to 90%,65,66 though overall success rates (12 months 
culture negative) with macrolide containing regimens range between 55 and 
83%.37,65,66,68,69  Perhaps the immunomodulating effect of macrolides could be beneficial 
to some patients with bronchiectasis associated with NTM lung disease.   
 
When multiple drugs are prescribed at once in a treatment naive patient, gastrointestinal 
intolerance frequently results. Many experts would recommend a stepwise introduction to 
therapy. Clarithromycin seems to be the agent most patients have problems with, and it 
may be necessary to start at a dose of 250mg twice daily, increasing to 500mg twice daily 
after 1-2 weeks, prior to the introduction of companion drugs. Whilst this approach 
would not be acceptable for tuberculosis, because of the risk of development of resistance, 
macrolide resistance in MAC develops comparatively slowly.65,66 
Secondly, there has also been no demonstrated superiority of one rifamycin (rifabutin or 
rifampicin) in the treatment of MAC lung disease, but because of frequent adverse events 
(uveitis, leucopenia, etc), most experts recommend the use of rifampicin.70,71 The roles 
for other medications such as fluoroquinolones and clofazimine in the treatment of MAC 
lung disease have not been fully explored, notwithstanding a report on the clinical 
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efficacy of clofazimine,69 the recent BTS study63 which included ciprofloxacin, and a few 
reports regarding the in vitro and in vivo efficacy of moxifloxacin against MAC.72,73 
The issue of whether an aminoglycoside should be used in the initial phase of treatment 
also needs to be addressed. The majority of early macrolide studies performed in the US, 
included a 2-3 month period of intermittent injectable aminoglycoside. The JTS 
guidelines from 1998 recommend initial streptomycin/kanamycin, with oral 
ERclarithromycin. Kobashi59 compared outcomes between patients treated 1993-1998, 
prior to these guidelines (when only 2.8% of patients received this combination) to those 
treated 1998-2003 (64.5% patients received combination). Sputum conversion rates, 
relapse rates and overall outcomes were better in the cohort treated with the 
recommended regimen. A Japanese RCT74 randomised patients to receive 
ERclarithromycin with or without intramuscular streptomycin for the first 3 months. 
Sputum conversion was significantly higher in those that received aminoglycoside, 
however, overall outcomes and relapse/reinfection rates were similar between the 2 
groups at study conclusion. None of the BTS studies have used aminoglycosides, and the 
BTS does not include a role for these injectables in treatment guidelines.  
 
For hypersensitivity pneumonitis due to MAC, the treatment strategy appears somewhat 
different.  Removal of the subject from environmental exposure to the contaminating 
source is mandatory.  Corticosteroids and/or anti-mycobacterial drugs might be required 
to bring about improvement of the disease.37 When the latter are needed, a shorter 
regimen of 3-6 months may be appropriate.75 
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M. kansaii lung disease
For patients with lung disease due to rifampicin susceptible M. kansasii, treatment 
recommendations are summarised in Table 4. The ATS/IDSA recommend a daily 
regimen including rifampicin 10 mg/kg/day (maximum, 600 mg), ethambutol 15 
mg/kg/day, isoniazid 5 mg/kg/day (maximum, 300 mg), assuming normal underlying 
liver and renal chemistries.37 The treatment duration for M. kansasii lung disease should 
include 12 months of negative sputum cultures.  There have been no prospective studies 
evaluating the efficacy of 18 months of therapy versus shorter (9 or 12 months) treatment 
durations.  One small study demonstrated that adding intermittent streptomycin twice 
weekly for the first 3 months to the three-drug regimen given for 12 months resulted in 
apparent cure in 98% cases.76 
The BTS guidelines recommend a combination of ethambutol and rifampicin given for 9 
months.61 This is largely based on a prospective study organised by the British Thoracic 
Society in which good results (99% sputum culture conversion) were achieved.77 
However, the relapse rate of 10% still appeared high and for many physicians, 
unacceptable, compared to results achieved with longer duration of therapy with the 
addition of isoniazid.  
 
For patients with rifampicin-resistant M. kansasii disease, a three-drug regimen is 
recommended by the ATS, based on in vitro susceptibilities including clarithromycin or 
azithromycin, moxifloxacin, ethambutol, sulphamethoxazole and streptomycin.37 High-
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dose isoniazid, high-dose ethambutol and sulphamethoxazole combined with prolonged 
streptomycin / amikacin administration gave good results in one report.78 M. kansasii 
generally is quite susceptible in vitro to clarithromycin.  A recent preliminary study on 18 
patients receiving three-times-weekly therapy with rifampicin (600 mg), ethambutol (25 
mg/kg), and clarithromycin (500 – 1,000 mg) reported that 12 months of negative sputum 
cultures was associated with no disease relapses at 46±8 months (mean±SD) follow-up.79 
Moxifloxacin and linezolid80 are also promising agents based on in vitro data, but clinical 
data are still lacking.  
 
M. malmoense, M. szulgai, and M. xenopi lung diseases
M. malmoense strains have variable susceptibility patterns to antimicrobials.  
They have shown susceptibility in vitro to ethambutol, ethionamide, kanamycin and 
cycloserine and resistance to isoniazid and rifampicin.81 Pulmonary disease due to M. 
malmoense can be difficult to treat.37 A combination of  rifampicin, and ethambutol with 
or without isoniazid has shown some effectiveness.12,42,82 There have been two 
randomised controlled trials performed by the BTS. The first compared ER to ERH, and 
the outcomes were similar between the two groups, with 42% of patients alive and cured 
at 5 years.42 This study demonstrated no correlation between in vitro antibiotic 
susceptibilities to individual drugs and clinical response. The second, more recent study, 
compared the addition of ciprofloxacin or clarithromycin to ER (again with the option of 
M. vaccae in each arm).63 The proportion of people alive and cured at 5 years was 38.4% 
in the clarithromycin arm and 19.8 % in the ciprofloxacin arm. The authors conclude that 
there is little difference between ER, ERH and ERclarithromycin in terms of outcome, 
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but the use of clarithromycin is likely to be associated with increased side effects.  
 
M. szulgai is susceptible in vitro to most antituberculosis drugs, as well as to 
fluoroquinolones and macrolides.83,84 Although the optimal duration of therapy has not 
been delineated, a 3- or 4-drug regimen that includes 12 months of negative sputum 
cultures while on therapy appears adequate.37 
 
M. xenopi has variable drug susceptibility testing results that are hard to interpret, 
especially regarding the first-line antituberculous agents.37 The clinical response to 
treatment does not always correlate well with drug susceptibility testing results.  Patients 
with disease due to M. xenopi were also included in the two BTS randomised controlled 
trials; however the numbers were small in this group. The BTS approach to treatment has 
been to use standard drugs in combination – ER ± isoniazid,61 however the more recent 
study suggests that clarithromycin may have a role.63 The ATS proposed regimen is a 
combination of ER,isoniazid and clarithromycin ± an initial course of streptomycin.37 
Moxifloxacin also has good in vitro activity against M. xenopi.85 Nevertheless, the 
mortality of lung disease due to M. xenopi can be high and the outlook from treatment is 
poor, possibly reflecting severe underlying pulmonary conditions.42,86 
Lung diseases due to rapidly growing mycobacteria
The three main species of RGM causing pulmonary diseases are M. abscessus, M. 
chelonae and M. fortuitum. Treatment relies heavily on guidance from antimicrobial 
susceptibility testing as there are virtually no large-scale clinical studies.  Most data 
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emerge from case reports87,88 or small series.13 The treatment of M. abscessus 
particularly can be quite difficult as it is highly resistant to antituberculous drugs. 
Treatment usually involves a combination of amikacin, cefoxitin/imipenem, and 
clarithromycin. However, this is difficult to administer or tolerate for long periods.  
 
M. fortuitum can be more amenable to treatment as antimicrobial susceptibility testing 
often provides a much wider range of oral agents to choose from, including the 
macrolides, newer quinolones, doxycycline, minocycline and sulphonamides.  Table 5 
shows a summary of proposed treatment, inclusive of choice of drugs with duration, and 
use of surgery.  The goal of 12 months of negative sputum cultures while on therapy may 
be reasonable37,89 for M. fortuitum. However few medication strategies for M. abscessus 
appear to be tolerable to achieve this goal reliably.  Isolated case reports of successful 
treatment without relapse using shorter duration of therapy have been noted.87,88  It might 
be more realistic to consider intermittent treatment courses during exacerbations of the 
disease, especially when parenteral drugs are involved.37 Expert consultation is 
recommended for the management of patients with this disease.  
 
Side effects and drug interactions. 
Table 6 depicts the possible adverse reactions of drugs commonly used in the treatment 
of NTM lung diseases.  The BTS recommended combination of rifampicin, and 
ethambutol only for treatment of lung diseases due to MAC, M. xenopi and M. 
malmoense has managed to produce cure rates of 30 – 40%.12,42,90  All-cause mortality 
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has been up to 40% but disease-related mortality has stayed low.  Nevertheless drug 
tolerance was reasonable, especially when only rifampicin and ethambutol were used. 
The addition of clarithromycin or ciprofloxacin resulted in a doubling of drug side 
effects.63 Curiously, the combination of ethambutol with clarithromycin resulted in more 
ocular toxicity than with ciprofloxacin, though there were some difficulties with 
documentation of ethambutol as a direct cause of visual problems. It is thus uncertain 
whether the conventional ER regimen should be completely abandoned.  Macrolides can 
be quite toxic in elderly subjects, and dosage adjustment is often required.91,92 
Ethambutol is reportedly less oculotoxic when given on an intermittent basis,93 and this 
may be advantageous in older patients.  
 
Rifampicin, while commonly administered with clarithromycin , has been shown 
to reduce the serum levels of the macrolide, through induction of cytochrome P-450 
enzymes.94 However, the clinical significance of this interaction remains unknown.  
Laboratory data also revealed that the interaction of rifabutin with clarithromycin was 
less.  Other drug-drug interactions of clinical significance involving clarithromycin in the 
treatment of patients with MAC disease have also been reported (Table 7), largely in 
HIV-infected patients.95 Compared to clarithromycin, azithromycin has fewer 
pharmacokinetic interactions, does not appear to prolong the QT interval as much, and 
may be better tolerated overall.  
 
Adjunctive Therapies 
 A substantial proportion of patients with pulmonary NTM diseases have 
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significant bronchiectasis causing morbidity, thus mucus clearance strategies are likely to 
be beneficial.  These methods include conventional chest physiotherapy and postural 
drainage, augmented by autogenic drainage and active cycle of breathing techniques; 
mucus clearance devices;96 and inhaled medications such as mannitol97 or hypertonic (7%) 
saline.98  Nutritional status should also be monitored in the management of pulmonary 
disease.  Attention to conditions that cause aspiration may also help to minimise 
pulmonary contamination or prevent re-infection in treated patients. So far, none of the 
adjunctive interventions has been specifically evaluated in patients with pulmonary NTM 
diseases, and such studies may be warranted. 
 
Surgical Treatment 
Surgical resection of limited (focal) pulmonary NTM disease (especially upper 
lobe cavitary disease) in a patient with adequate cardiopulmonary reserve can be 
successful in combination with multidrug treatment regimens for MAC and M. abscessus 
lung diseases.37,99 Surgical resection of a solitary pulmonary nodule due to MAC is 
indeed also considered by experts to be curative, though the data to support this 
assumption is lacking.37 Other indications for surgical resection include failure of medical 
therapy,99,100 serious intolerance to drugs for treatment,100 and macrolide-resistant MAC 
lung disease.67 Data have shown that, in light of good long-term results, surgery should 
be recommended before disease becomes exceedingly advanced and unresectable.101,102 
In addition, in extensive disease, the excision of large cavitary mycobacterial foci might 
assist medical management of remaining lesions.102 Despite bronchial stump protection, 
pneumonectomy still carries a risk for bronchopleural fistula.  However, pneumonectomy 
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does help to confer high cure rates in patients with NTM lung diseases.103 Surgery 
should, therefore, be performed in centres with considerable medical and surgical 
expertise in the management of patients with NTM disease.37 
Issues for Future Exploration 
Currently the evaluation of a patient with a positive sputum culture for NTM is costly and 
time consuming. Patients require further sputum specimens and often CXRs and CT 
scans to fully evaluate for the presence/absence of disease. When there is doubt these are 
often repeated over time. Smear-positive specimens create extra testing (DNA probes 
where available) to differentiate the pathology from tuberculosis, and where these tests 
are not available, many patients receive unnecessary treatment and public health 
management resources in the assumption they have tuberculosis, until mycobacterial 
cultures confirm otherwise. Better diagnostic tests that obviate the need for these costly 
investigations would significantly improve health care in this area.  
 
Serodiagnosis of MAC pulmonary disease using an enzyme immunoassay to assess 
antibody response to glycopeptidolipid has been shown to be promising, though 
validation in larger populations still appears warranted. The most recent of four papers 
published from Japan,104 consisted of  a multicentre study, which evaluated this test in 
70 patients with MAC pulmonary disease (19 with fibrocavitary disease, 35 with nodular 
bronchiectasis, 16 unclassifiable), 18 considered contaminated with MAC, 36 patients 
with pulmonary tuberculosis, 45 with other lung diseases and 76 healthy controls. In 
discriminating MAC pulmonary disease from the other patient groups – the test 
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demonstrated 84.3% sensitivity and 100% specificity (using a cut-off level of 0.7U/ml). 
Significantly higher levels were found in nodular bronchiectasis than in cavitary disease, 
but there was no difference between M. avium and M. intracellulare. There was a positive 
correlation between antibody levels and radiographic extent of disease in patients who 
had CT and serodiagnosis at the same time. Future studies are needed to verify the chosen 
cut-off point from this study, using larger samples of cases and controls that encompass 
multiple underlying lung diseases, along with patients from more diverse ethnic and 
racial groups and geographic areas. 
 
As mycobacteria are ubiquitous and of low virulence it is presumed that a host 
defect of immune regulation must be present for disease to occur, particularly in patients 
with the nodular-bronchiectatic form, who are largely non-smokers, with no predisposing 
conditions. Defects in the interferon–N (IFNN) and Interleukin-12 (IL-12) receptor 
pathways have been reported in cases of disseminated NTM infection in young patients. 
Unfortunately no similar defect has been found in patients with pulmonary NTM 
infection.  Kwon, et al105 investigated the ability of peripheral blood mononuclear cells to 
produce proinflammatory cytokines such as IFNN, tumour necrosis factor-alpha (TNFO)
and IL-12, and anti-inflammatory cytokines such as IL-10 in NTM patients and controls. 
They confirmed the findings of previous investigators106,107- that patients with NTM 
pulmonary diseases (both MAC and M.abscessus) produce less IFN-N, TNF-O and IL-12 
than healthy controls. This opens up a possible therapeutic approach, by including 
exogenous cytokine replacement. Aerosolised interferon-, as adjunctive therapy for 
MAC lung disease, appeared initially promising,108 but a randomised controlled trial of 
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aerosolised interferon- was halted early because of lack of efficacy.64 The efficacy of 
systemically administered cytokines is limited to studies in mice.109,110 However further 
evaluation of immunotherapy of NTM lung diseases appears warranted.   
 
As NTM lung diseases are generally difficult to treat, new drugs are needed to 
advance therapy.  Aside from moxifloxacin as discussed, linezolid, a oxazolidinone, has 
been shown to have good activities against many rapidly111,112 and slowly growing 
mycobacteria.113 However there are major problems to consider when using linezolid in 
the longer term, such as anaemia and peripheral neuropathy.  Tigecycline, a glycylcycline 
has been shown to have promising activity against RGM, especially for M. abscessus and 
M. chelonae.114 TMC207, a diarylquinoline developed for treatment of tuberculosis, 
incidentally has been found to have activity against some NTM,115 and might have 
potential in treating diseases caused by these organisms. Inhaled antimicrobial therapy 
has appeared attractive to some investigators.116 A preliminary observational case series 
regarding the efficacy of aerosolized amikacin against MAC lung diseases has been 
reported.117 
Finally, randomised controlled trials in well described patients would provide 
stronger evidence-based data to guide therapy of NTM lung diseases, and thus are much 
needed. Elucidation of the mechanism behind host susceptibility will also add invaluable 
information, so therapy can be directed towards the underlying cause for establishment of 
infection. Environmental factors contributing to the increased prevalence of infection 
should also be explored, so as to reduce reinfection of susceptible patients who are 
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successfully treated. Newer therapies, optimised management of comorbid conditions, 
and a more holistic approach should be explored in the hope of improving treatment 
outcomes of these NTM lung diseases.  
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Figure 1.  Xray and CT scan of a patient with the cavitary form of pulmonary NTM disease, in 
association with COPD. 
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Figure 2. Chest Xray and CT cuts of a patient with the Fibro-nodular Bronchiectatic form of pulmonary 
NTM disease. 
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Table 1. Classification of Mycobacterial Species Commonly Causing Human Disease.
M. tuberculosis complex
• M. tuberculosis
• M. bovis
• M. africanum
• M. microti
Slowly growing mycobacteria
Runyon Group 1, Photochromogens
• M. kansasii
• M. marinum
Runyon Group II, Scotochromogens
• M. gordonae
• M. scrofulaceum
Runyon Group III, Nonchromogens
• M. avium complex – M.avium, M.intracellulare
• M. terrae complex
• M. ulcerans
• M. xenopi
• M. simiae
• M. malmoense
• M. szulgai
• M. asiaticum
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Rapidly Growing Mycobacteria
Runyon Group IV
• M. fortuitum
• M. chelonae
• M. abscessus
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Table 2. Summary of the ATS/IDSA Criteria for Diagnosis of Pulmonary NTM Diseases
Clinical and Radiographic (both required):
 Pulmonary symptoms, nodular or cavitary opacities on chest radiograph, or a HRCT scan 
that shows multifocal bronchiectasis, alongside multiple small nodules,  
AND
 Appropriate exclusion of other diagnoses, especially tuberculosis and mycosis
Microbiological
 Positive culture results from at least two separately expectorated sputum samples.  If results 
are nondiagnostic, consider repeat smears and cultures
OR
 Positive culture results from at least one bronchial wash or lavage
OR
 Transbronchial or other lung biopsy with mycobacterial histopathological features 
(granulomatous inflammation or stainable acid-fast bacilli), and positive culture for NTM, 
or biopsy showing mycobacterial histological features, and 1 sputum or bronchial 
washings that are culture positive for NTM.
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Table 3. Recommended Treatment Regimens for Pulmonary MAC Disease 
ATS
Initial treatment 
of Nodular BE*
ATS
Initial treatment of 
Cavitary disease
ATS
Advanced (severe) or 
pretreated disease
BTS JTS
Macrolide Clar 1000mg TIW
Or
Azi 500-600mg 
TIW
Clar 500†-1000mg/d
Or
Azi 250†-300mg/d
Clar 500†-1000mg/d
Or
Azi 250†-300mg/d
None‡ Clar 10mg/kg/d
Ethambutol 25mg/kg/d
TIW
15 mg/kg/d 15 mg/kg/d 15mg/kg/d 15mg/kg/d
Rifamycin Rifampicin 
600mg TIW
Rifampicin  450† -
600mg/d
Rifabutin 250-300mg/d 
or Rifampicin 450†-
600mg/d
Rifampicin  450† -
600mg/d
Rifampicin 
10mg/kg/d
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Aminoglycoside None None or Amikacin or 
Streptomycin§
Amikacin or 
Streptomycin
Streptomycin or
kanamycin**
Other drugs Isoniazid 300mg/d or 
Ciprofloxacin 750mg 
bd††
Duration 12 months culture 
negative 
12 months culture 
negative
12 months culture 
negative
2 years 2 years
*
 Not recommended for severe/advanced/previously treated disease
†
 Lower dose for body weight < 50kg
‡
 If intolerance to rifampicin or ethambutol, clarithromycin or ciprofloxacin may be substituted 
§
 Given intermittently for the first 2-3 months
** Given intermittently for the first 2-6 months
††
 May be added if the patient is responding poorly at 12 months;
Clar = Clarithromycin
Azi = Azithromycin
TIW = three-times weekly
BD = two-times daily
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Table 4.  Recommended Treatment Regimens for Rifampicin-susceptible Mycobacterium 
kansasii Pulmonary Disease.
ATS BTS
Ethambutol 15mg/kg/d 15mg/kg/d
Rifampicin 10mg/kg/d (max 600mg) 450*-600mg/d
Isoniazid† 5mg/kg/d (max 300mg/d)
Duration 12 months culture negative 9 months
*
 Lower dose for body weight < 50kg
†
 Plus pyridoxine 50mg/d
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Table 5. Treatment of Diseases due to Rapidly Growing Mycobacteria
Active Drugs Duration Surgery
M. abscessus Clarithromycin*
Amikacin*
Cefoxitin*
Imipenem 
Linezolid†
4 mo (soft tissue)
6 mo (bone)
? 12 mo (lung)
++
M. chelonae Tobramycin*
Clarithromycin* 
Linezolid†
Imipenem
Amikacin
Clofazimine
Doxycycline
Ciprofloxacin
4 mo (soft tissue)
6 mo (bone)
? 12 mo (lung)
+
M. fortuitum Amikacin*
Ofloxacin* / Ciprofloxacin*
Imipenem*
Sulphonamides
Clarithromycin
Doxycycline
4 mo (soft tissue)
6 mo (bone)
? 12 mo (lung)
+
* quite active agents †  newer active agent
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Table 6. Adverse Reactions to Drugs Used for Treatment of NTM Diseases
Reactions
Drug
Common  Rare
Isoniazid Hepatitis
Cutaneous hypersensitivity
Peripheral neuropathy
Dizziness
Convulsion
Optic neuritis
Mental symptoms
Haemolytic anaemia
Aplastic anaemia
Lupoid reactions
Arthralgia
Gynaecomastia
Rifampicin Hepatitis
Cutaneous hypersensitivity
Gastrointestinal reactions
Thrombocytopenic purpura
Febrile reactions
“Flu syndrome”
Shortness of breath
Shock
Haemolytic anaemia
Acute renal failure
Rifabutin Abnormal taste
Arthralgia
Uveitis
Leucopenia
Thrombocytopenia
“Flu syndrome”
Hepatitis
Shock
Haemolytic anaemia
Ethambutol Retrobulbar neuritis
Arthralgia
Hepatitis
Cutaneous reaction
Peripheral neuropathy
Streptomycin Cutaneous 
hypersensitivity 
Dizziness
Numbness
Tinnitus
Vertigo
Ataxia
Deafness
Renal damage
Aplastic anaemia
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Amikacin
Kanamycin
Capreomycin
Ototoxicity: hearing loss, 
vestibular disturbance
Nephrotoxicity: deranged 
renal function 
Clinical renal failure
Hypokalaemia
Hypocalcaemia
Hypomagnesaemia
Clarithromycin Nausea
Dyspepsia
Diarrhoea
Abdominal pain
Rash
Hepatic dysfunction
Hearing loss
QT prolongation
Azithromycin Nausea Diarrhoea
Abdominal pain
Rash
Hepatic dysfunction
Tinnitus
Hearing loss
Ofloxacin
Ciprofloxacin
Gastrointestinal reactions
Insomnia
Oral candidiasis
Anxiety
Dizziness
Headache
Tremor
Convulsion
Haemolysis
Tendonitis / Tendon 
rupture
Arthropathy
Colitis
Levofloxacin
Moxifloxacin
Similar to those of ofloxacin or ciprofloxacin except less central nervous 
system dysfunction
Clofazimine Photosensitisation
Hyperpigmentation
Cutaneous reactions
Gastrointestinal 
reactions
Retinopathy
Intestinal obstruction
Linezolid Diarrhoea
Dyspepsia
Headache
Thrombocytopenia
Aplastic anaemia*
Colitis
Peripheral and optic 
neuropathies*
* more common with prolonged administration
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Table 7 Examples of Drug-Drug Interactions Involving Clarithromycin in Treatment 
of MAC Disease 
Drug Result 
 Rifabutin  level of rifabutin 
 Statin lipid-lowering agents  level of statins 
 Cyclosporine  level of cyclosporine 
 Terfenadine  level of terfenadine 
 Nevirapine  level of clarithromycin 
 Efavirenz  level of clarithromycin 
 Itraconazole  level of clarithromycin 
 Delavirdine ±  level of clarithromycin 
 HIV protease inhibitors ±  level of clarithromycin 
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